SEOUL (Reuters) – The first of three expert panels in South Korea gave its recommendation on Monday for the government to grant approval of the Moderna COVID-19 vaccine based on safety and efficacy of the shots in the U.S. phase 3 trial.
The national pharmaceutical panel is scheduled to make its recommendation on Thursday, but the government will wait for a third panel, which has not said when it will reach its conclusion, before deciding whether to grant approval.
(Reporting by Sangmi Cha; Editing by Kim Coghill)
